Sign in
Taking people in United StatesPhase 1/2

How the body responds to deer tick bites in healthy adults

Studies skin and immune reactions to lab-raised tick bites in healthy adults.

Key facts

Who runs it
National Institute of Allergy and Infectious Diseases (NIAID)
Where
Bethesda, United StatesSee the site
Trial code
Registry title
Human Immune Response to Ixodes Scapularis Tick Bites
Status
Recruiting
Phase
Phase 1/2
People taking part
60 people, planned
Started
28 Feb 2022
Expected to end
30 Jun 2029
Type of study
InterventionalOne group gets an existing treatment, for comparison.
Treatments tested
  • Xenodiagnosis Ticks
  • skin biopsy
  • blood draw
Record updated
22 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy adults who have never had a tick-borne disease or a known tick bite. Clean lab-bred ticks will be placed on the skin to study how the body responds.

Age
18 years or older (up to 99 Years)
Sex
All
Disease stage
Healthy volunteers only, in good general health. No history of tick-borne disease and no known tick bite.
Earlier treatment
No anticoagulants (blood thinners) in the past 28 days. No other investigational drug or intervention in the past 30 days. No oral or IV steroids in the 2 weeks before each tick placement.
Biomarker or test result
Serum IgE and serum tryptase levels must be in the normal range. Hemoglobin at least 13.0 g/dL for males and 12 g/dL for females.

Main reasons for not taking part

  • Pregnancy or breastfeeding
  • History of keloid scars or excessive bleeding
  • Allergy to lidocaine, tape or dressings, or serious allergies such as anaphylaxis, mammalian meat or venom reactions
  • Moderate to severe asthma, atopic dermatitis or allergic rhinitis
  • History of HIV, chronic viral hepatitis, syphilis, cancer (other than non-melanoma skin cancer) or uncontrolled diabetes

This trial only enrols healthy participants. The registry sentence this rests on: 3. In good general health as evidenced by medical history.

The registry criteria, word for word

Show all 29 criteriaShow less

Who cannot take part

  • Treatment with another investigational drug or other intervention within the past 30 days
  • Oral or intravenous (IV) steroids in the 2 weeks prior to each tick placement procedure (topical, nasal, inhaled, intra-articular, and replacement doses of steroids are not exclusions)
  • Any other condition that, in the opinion of the investigator, would make the patient unsuitable for enrollment or could interfere with the patient participating in and completing the study; Exclusion of Select Populations:; Children:; Children are excluded from this protocol as there is no direct benefit to the participants, the risk from the skin biopsies is small but above minimal, the procedure is invasive and can be stressful for children, and there is concern over their ability to maintain the LeFlap dressing; Pregnant and breastfeeding women:; Pregnant and breastfeeding women are excluded from trial participation as there is no direct benefit to the participants; Adults who lack or lose decision-making capacity to consent to research participation:; Adults lacking decision-making capacity to provide informed consent are excluded at screening as there is no direct benefit to the participants. Enrolled participants who permanently or temporarily lose the ability to consent after receiving the first tick exposure procedure will be advised to continue study visits for safety monitoring but will have no additional research procedures performed
  • History of forming large thick scars (keloids) after skin injuries
  • History of excessive bleeding after cuts or procedures
  • History of taking anticoagulants in the past 28 days
  • History of allergic reaction to lidocaine
  • History of allergic reaction to tape, adhesive bandages, or dressings
  • History of reactions to mammalian meat, IgE- mediated food allergies, urticaria or anaphylaxis. Mild pollen-food allergy syndrome is not an exclusion
  • History of systemic allergic reaction to venom (bee, wasps and other Hymenoptera stings)
  • History of clinically significant drug allergies
  • History of moderate to severe atopy asthma, atopic dermatitis, allergic rhinitis
  • Active severe skin disease, uncontrolled diabetes, cancer other than non-melanoma skin cancers, autoimmune disease requiring immunosuppressive therapy, or history of human immunodeficiency virus (HIV), chronic viral hepatitis, or syphilis
  • An individual who meets any of the following criteria will be excluded from participation in this study:
  • Inability to maintain the dressing for any reason
  • Pregnancy or lactation
  • Refusal to allow storage of samples and data for future usage

Other criteria

  • INCLUSION CRITERIA:; In order to be eligible to participate in this study, an individual must meet all of the following criteria:
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Age 18 years or older
  • In good general health as evidenced by medical history
  • No history of TBD
  • No known tick bite
  • Serum IgE level within Clinical Center Department of Laboratory Medicine normal range; https://ccinternal2.cc.nih.gov/LTGRA/UL/public_labtest_detail.aspx?next_flg=Y\&test_id=4731\&id_order=53
  • Serum tryptase level within Clinical Center Department of Laboratory Medicine normal range; https://ccinternal2.cc.nih.gov/LTGRA/UL/public_labtest_detail.aspx?next_flg=Y\&test_id=1157\&id_order=1
  • For participants of child-bearing potential: use of effective contraception for at least 1 month prior to tick placement, and agreement to use such a method during study participation and for an additional 3 months after the removal of the last ticks. Types of contraception include abstinence, surgical methods (sterilization, implants, intrauterine device, partner with vasectomy), hormonal methods (birth control pill, patch, ring, injection), or barrier methods (diaphragm plus spermicide, male condom plus spermicide)
  • For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner
  • Agree to not participate in other clinical studies requiring investigational interventions for the duration of the study
  • Minimum hemoglobin of 13.0 g/dL for males and 12 g/dL for females

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 99 years old?

Where in United States

  • National Institutes of Health Clinical CenterBethesda, United StatesContact: Siu-Ping Ng, R.N.Taking people

About the trial

What the trial wants to find out

Background:

Read full original descriptionShow less

Each year, the number of cases of tick-borne diseases increases. The deer tick (Ixodes scapularis) is the vector of at least 7 pathogens that cause human diseases, including Lyme disease. Researchers want to learn more to help them develop vaccines against ticks in the future.

Objective:

To learn how people s bodies, particularly the skin, respond to tick bites.

Eligibility:

Healthy adults aged 18 years and older who have no known history of a tick-borne disease or tick bite exposure.

Design:

Participants will be screened with a medical history, physical exam, and blood tests.

Participants will have 2 skin punch biopsies of healthy skin. For this, a sharp instrument will be used to remove a round plug of skin about the size of a pencil eraser. Participants will then have 10 clean laboratory-bred ticks placed at 2 different sites on their skin (20 ticks total). The ticks will be removed from the first site 1 day after placement and from the second site 2-4 days after placement. Participants will complete symptom diary cards. They will answer questions about itching at the tick feeding sites. They will give blood samples. Photos will be taken of the tick feeding sites. Skin punch biopsies will be collected at the sites of the tick bites.

Participants will repeat the tick feeding procedures 2 times, each 2-8 weeks apart. For the 2nd and 3rd procedures, 10 clean laboratory-bred ticks will be placed at 1 site. The ticks will be removed 2-3 days after tick placement. They will have telephone follow-up visits after each procedure.

After the final tick removal, participants will have follow-up visits in 4-6 weeks and again in 3 months. They will give blood samples and discuss how they are feeling.

Participation will last about 5-7 months.

The group in the trial

  • 1Existing treatment, for comparison

    Healthy Volunteer

    Treatment: Xenodiagnosis Ticks, skin biopsy, and blood draw

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Investigating the Human Immune Response to Ixodes Scapularis Tick Bites
Plain-language title
How the body responds to deer tick bites in healthy adultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT05036707, who can take part
Record updated
22 September 2026